知镜 Cognispect · 医学文献与研究工作台

Upadacitinib and shikonin co-loaded nanodrug for rheumatoid arthritis therapy via attenuating inflammation and protecting cartilage.

Li M, Tang Y, Lin Y, Yang M, Yan P, Liu L, Liu L, Liu B, Cai X.
Biomaterials · 2026-09-16 · PMID 42777453

文献摘要

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, excessive oxidative stress, and progressive joint destruction. Although upadacitinib (UP) monotherapy exhibits robust anti-inflammatory efficacy, its systemic administration is limited by a narrow target profile and hepatotoxicity. To address these challenges, we rationally designed a biomimetic nanodrug (HA-M@SHK-Fe@BSA-UP NPs) co-delivering UP with shikonin (SHK), a natural naphthoquinone with antioxidant activity and hepatoprotective effects. This nanoplatform self-assembled via iron-mediated metal-phenolic coordination, using bovine serum albumin (BSA) as a bridge, with a dual-surface modification of erythrocyte/macrophage hybrid membrane (M) and hyaluronic acid (HA). This architecture enabled prolonged circulation and pH-responsive drug release. In vitro, the nanodrug exhibited efficient reactive oxygen species (ROS) scavenging and targeted cellular uptake. Mechanistically, the nanodrug acted on macrophages and primary rat knee-joint chondrocytes (PRKCs) in parallel. It effectively drove M1-to-M2 polarization at least in part through the JAK1/STAT3/PKM2 axis and directly restored the function of PRKCs to suppress matrix degradation. In vivo, Ce6-based fluorescence imaging showed that the nanodrug accumulated 4.55-fold more in arthritic joints than free Ce6. Moreover, this nanodrug significantly suppressed inflammation at a low dosage and promoted cartilage and bone repair in AIA and CIA rat models, while showing reduced signs of liver injury. In summary, this self-assembled nanodrug offers a promising strategy for inflammatory disease treatment.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。